Impact of dopamine transporter SPECT using 123I-Ioflupane on diagnosis and management of patients with clinically uncertain parkinsonian syndromes

Ana M. Catafau, Eduardo Tolosa, Patrice Laloux, Thierry Vander Borght, Michel Van Zandijcke, Frank De Geeter, Alain Destee, Marc Steinling, Lucette Lacomblez, Marie Odile Habert, Cornelius Weiller, Malte Clausen, Ulrich Bogdahn, Anton Haass, Carl Martin Kirsch, Angelo Antonini, Riccardo Benti, Sandro Sorbi, Alberto Pupi, Luís CunhaJoao Pedroso de Lima J.P., Frances Vallderiola, Francisco Lomeña, Jaime Kulisevsky, Ana M. Catafau, Robert Weeks, Muriel Buxton-Thomas, William R G Gibb, Paul M. Kemp, Susanne Asenbaum, Robert Dudczak

Research output: Contribution to journalArticle

Abstract

Imaging with 123I-Ioflupane single-photon emission computed tomography (SPECT) is a marker of nigrostriatal neuronal integrity, allowing differentiation of parkinsonism with loss of dopaminergic terminals (presynaptic Parkinson syndrome [PS] from parkinsonism without nigrostriatal degeneration. This study assessed SPECT imaging in 118 patients with clinically uncertain parkinsonian syndromes (CUPS). In 36% of patients with presynaptic PS and 54% with nonpresynaptic PS, imaging results were not consistent with the initial diagnosis. After imaging, diagnosis was changed in 52% of patients. All patients with a final diagnosis of presynaptic PS had an abnormal image, whereas 94% of patients with nonpresynaptic PS had a normal scan. Imaging increased confidence in diagnosis, leading to changes in clinical management in 72% of patients. Consequently, visual assessment of 123I-Ioflupane SPECT may have a significant impact on the clinical management of CUPS patients.

Original languageEnglish
Pages (from-to)1175-1182
Number of pages8
JournalMovement Disorders
Volume19
Issue number10
DOIs
Publication statusPublished - Oct 2004

Keywords

  • I-Ioflupane
  • Dopamine transporter
  • Parkinsonism
  • SPECT

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Fingerprint Dive into the research topics of 'Impact of dopamine transporter SPECT using <sup>123</sup>I-Ioflupane on diagnosis and management of patients with clinically uncertain parkinsonian syndromes'. Together they form a unique fingerprint.

  • Cite this

    Catafau, A. M., Tolosa, E., Laloux, P., Vander Borght, T., Van Zandijcke, M., De Geeter, F., Destee, A., Steinling, M., Lacomblez, L., Habert, M. O., Weiller, C., Clausen, M., Bogdahn, U., Haass, A., Kirsch, C. M., Antonini, A., Benti, R., Sorbi, S., Pupi, A., ... Dudczak, R. (2004). Impact of dopamine transporter SPECT using 123I-Ioflupane on diagnosis and management of patients with clinically uncertain parkinsonian syndromes. Movement Disorders, 19(10), 1175-1182. https://doi.org/10.1002/mds.20112